ARCA shareholders approve merger with Oruka; 1-for-12 reverse split set for Sept 3 trading under ORKA

Oruka Therapeutics, Inc.

Shareholders approved all 9 proposals at Aug 22 special meeting, including merger, share increase to 545M, and reverse split.
Board set reverse stock split ratio at 1-for-12; outstanding shares to drop from ~14.5M to ~1.21M.
Post-merger combined company expected to have ~29.5M common shares, plus ~5.4M pre-funded warrants and ~11.4M Series B convertible shares.
Merger expected to close Aug 29; shares to trade as Oruka Therapeutics under ticker 'ORKA' on Nasdaq Global Market starting Sept 3.
New CUSIP 687604108 and ISIN US6876041087 assigned after reverse split; cash in lieu of fractional shares at Sept 3 closing price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.